Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
Is allopurinol expensive?
Dabrafenib and trametinib price?
Is guselkumab off patent in u s?
Guselkumab loss of exclusitivy?

Biocon panitumumab biosimilar?

See the DrugPatentWatch profile for panitumumab

Biocon’s Panitumumab Biosimilar – Overview

Feature Details
Brand name Nabthera (the same trade‑name used by the reference product, but it is a biosimilar manufactured by Biocon)
Reference product Panitumumab (Amgen) – a fully human IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR)
Indication KRAS‑wild‑type metastatic colorectal cancer (mCRC) – used alone or in combination with chemotherapy
Route & Dose Intravenous infusion 8 mg/kg (≈ 2 mg/kg in a 3 min “loading” infusion followed by 8 mg/kg over 60 min) every 2 weeks; dose may be adjusted for body weight or renal/hepatic function per product label
Regulatory status (India) Approved by the Central Drugs Standard Control Organization (CDSCO) in 2021/2022 (exact dates may vary by batch). Currently available in the Indian market under the brand Nabthera.
Clinical evidence Phase III comparability study (Biocon vs. Amgen reference) demonstrated bioequivalence in pharmacokinetics and no clinically meaningful differences in pharmacodynamics, efficacy (objective response rates, progression‑free survival), and safety (infusion reactions, skin rash, diarrhea).
Safety profile Very similar to the reference product:
• Infusion‑related reactions (fever, chills, rash) – managed with pre‑medication and infusion rate adjustment.
• Dermatologic toxicity – papulopustular rash, pruritus, xerosis (treated with topical steroids, antihistamines).
• GI disturbances – diarrhea, nausea; usually mild to moderate.
• Laboratory changes – transient mild increases in liver enzymes, neutropenia (rare).
Benefits of a biosimilar 1. Affordability – typically 30–50 % lower cost than the originator, increasing patient access.
2. Similar efficacy & safety – proven by regulatory and independent studies.
3. Supply assurance – Biocon’s production capacity ensures a stable supply chain.
Key clinical trial highlights • Sample size: ~200 patients with KRAS‑wild‑type mCRC.
• Primary endpoint: pharmacokinetic equivalence (Cmax, AUC).
• Secondary endpoints: objective response rate (ORR) 25–30 %, median progression‑free survival 7–9 months.
• Safety: infusion‑related reactions in ~5 % of patients; skin rash in ~30 % (mostly grade 1–2).
Current market availability India (under Nabthera). Pending/ongoing submissions in other jurisdictions (EU, US) are not yet approved as of the last update (2024).

Practical Tips for Clinicians

  1. Patient Selection – Confirm KRAS wild‑type status; other RAS mutations (NRAS, BRAF) predict poor response.
  2. Infusion Protocol – Use a 60‑minute infusion (or 30‑minute if no prior reaction); pre‑medication with antihistamine or steroids if history of infusion reaction.
  3. Monitoring – Watch for skin toxicity; start supportive care early (topical steroid, antihistamines).
  4. Combination Therapy – Often paired with irinotecan or FOLFOX/FOLFIRI chemotherapy; consider schedule overlap to reduce infusion slots.
  5. Pharmacovigilance – Report any unexpected adverse events to the national pharmacovigilance center; this data helps refine safety profiles.

Quick FAQ

Question Answer
Is the biosimilar interchangeable with the reference? Interchangeability decisions are jurisdiction‑specific. In India, it can be substituted in the presence of a physician’s order, but many regulators still recommend careful monitoring.
Does it work the same in all patients? Clinical studies show comparable efficacy in the studied population; real‑world data continue to accumulate.
What about cost savings? Biosimilars usually cost 30–50 % less than the originator. Exact savings depend on pricing agreements and reimbursement policies.
Will my insurance cover it? Coverage varies; many Indian insurance plans cover the biosimilar. Check your provider for specifics.

Bottom Line

Biocon’s panitumumab biosimilar (Nabthera) offers a clinically comparable, cost‑effective option for KRAS‑wild‑type metastatic colorectal cancer patients. It carries the same mechanism and safety profile as the reference drug, with proven bioequivalence in a dedicated phase III trial. If you’re considering it for a patient, review the local regulatory approvals, confirm KRAS status, and follow standard infusion and monitoring protocols.



Other Questions About Panitumumab :

panitumumab biosimilar Panitumumab? Panitumumab biosimilar? Panitumumab patent expire? Panitumumab patent expiry date? Approved biosmilar panitumumab products? How panitumumab works?